Garrison Point Advisors
MRNA icon

Garrison Point Advisors’s Moderna MRNA Stock Holding History

Garrison Point Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$453K Buy
+2,350
New +$253K 0.17% 120

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Garrison Point Advisors's MRNA Position: Q3 2026 in Review

Garrison Point Advisors opened a new position in Moderna (MRNA) in Q3 2026: 2,350 shares worth $453K. The stake represents 0.17% of the portfolio and ranks #120 among its holdings.

633 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Garrison Point Advisors held 2,350 shares of Moderna worth $453K as of Q3 2026.
  • Moderna was a new Garrison Point Advisors position in Q3 2026.
  • Moderna made up 0.17% of Garrison Point Advisors's portfolio in Q3 2026, its #120 holding.
  • 633 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Garrison Point Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.